The presence of multiple high-confidence TFBS within critical promoter regions provides mechanistic insight into how Hes and ADR combination therapy may exert coordinated transcriptional control, simultaneously attenuating proliferative (EGFR) and immunosuppressive (FOXP3) signaling axes in ovarian cancer cells. The gene discussed is FOXP3; the disease is ovarian carcinoma.